Aryl heterocyclic derivatives having anti-inflammatory effects, and methods of preparation and use thereof

By designing aromatic heterocyclic derivatives, the selectivity and toxicity issues of PDE4 inhibitors in existing technologies have been resolved, achieving highly selective inhibition of PDE4 and providing an effective treatment option for inflammatory diseases.

CN122404285APending Publication Date: 2026-07-17SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHENYANG PHARMA UNIV
Filing Date
2026-04-07
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to design highly selective, low-toxicity PDE4 inhibitors, thus failing to effectively treat inflammatory diseases associated with phosphodiesterase 4.

Method used

A class of aromatic heterocyclic derivatives was developed, which, through the design of compounds with specific structures, exhibit highly selective inhibitory activity against PDE4 and can be used to prepare PDE4 inhibitors.

Benefits of technology

It achieves highly selective inhibition of PDE4, reduces systemic side effects, and provides an effective treatment option for inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404285A_ABST
    Figure CN122404285A_ABST
Patent Text Reader

Abstract

本发明属于药物化学技术领域，涉及一类具有抗炎活性的芳杂环衍生物、包含其的药用组合物及其在制备用于预防或治疗磷酸二酯酶4（PDE4）相关疾病的药物中的应用。所述芳杂环衍生物表现出良好的PDE4抑制活性和抗炎作用。研究表明，该类化合物可有效调控炎症反应，适用于包括炎症性疾病在内的与PDE4相关疾病的预防或治疗。本发明所述化合物为通式（I）所示结构，或其药学上可接受的盐、几何异构体、对映异构体及其含氮芳杂环上的N‑氧化物。本发明化合物具有良好的应用前景，可用于开发新型高效、低毒的PDE4抑制剂类药物。通式（I）。
Need to check novelty before this filing date? Find Prior Art